149 Ces Urol 2023; 27(3): 139-150 PŘEHLEDOVÉ ČLÁNKY 25. Furniss D, Harnden P, Ali N, et al. Prognostic factors for renal cell carcinoma. Cancer Treatment Reviews. 2008; 34(5): 407–26. 26. Kirkali Z, Lekili M. Renal cell carcinoma: new prognostic factors? Current Opinion in Urology. 2003; 13(6): 433–8. 27. Rivet J, Mourah S, Murata H, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer. 2008; 112(2): 433–42. 28. Bensalah K, Rioux‑Leclercq N, Vincendeau S, et al. Is tumour expression of VEGF associated with venous invasion and survival in pT3 renal cell carcinoma? Progres En Urologie. 2007; 17(2): 189–93. 29. Kluger HM, Siddiqui SF, Angeletti C, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Laboratory Investigation. 2008; 88(9): 962–72. 30. Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World Journal of Urology. 2018; 36(12): 1943–52. 31. Hodorova I, Solar P, Mihalik J, et al. Investigation of tumour supressor protein p53 in renal cell carci‑ noma patients. Biomedical Papers‑Olomouc. 2014; 158(1): 44–9. 32. Gudowska‑Sawczuk M, Kudelski J, Mroczko B. The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2020; 21(22). 33. Bratu O, Mischianu D, Marcu D, et al. Renal tumor biomarkers (Review). Experimental and Therapeutic Medicine. 2021; 22(5). 34. Tschirdewahn S, Panic A, Pullen L, et al. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma. International Journal of Cancer. 2019; 145(2): 531–9. 35. Yang F, Song Y, Ge L, et al. Long non‑coding RNAs as prognostic biomarkers in papillary renal cell carcinoma. Oncology Letters. 2019. 36. Felekkis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded mole‑ cules that play a role in health and disease. Hippokratia. 2010; 14(4): 236–40. 37. Slaby O, Jancovicova J, Lakomy R, et al. Expression of miRNA-106 b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. Journal of Experimental & Clinical Cancer Research. 2010; 29. 38. Griffiths‑Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Research. 2008; 36: D154–D8. 39. Esquela‑Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nature Reviews Cancer. 2006; 6(4): 259–69. 40. Wang F, Zhang HX, Xu NH, et al. A novel hypoxia‑induced miR-147a regulates cell proliferation through a positive feedback loop of stabilizing HIF-1. Cancer Biology & Therapy. 2016; 17(8): 790–8. 41. Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. International Journal of Oncology. 2014; 44(1): 53–8. 42. Iwamoto H, Osaki M, Honda M, et al. miR-210 as a Biomarker in Renal Carcinoma. Biomarkers in Kidney Disease. 2016; 1–2: 895–910. 43. Lu J, Wei JH, Feng ZH, et al. miR-106 b-5p promotes renal cell carcinoma aggressiveness and stem ‑cell‑like phenotype by activating Wnt/beta‑catenin signalling. Oncotarget. 2017; 8(13): 21461–71. 44. Li YF, Chen DQ, Su ZM, et al. MicroRNA-106 b functions as an oncogene in renal cell carcinoma by affecting cell proliferation, migration and apoptosis. Molecular Medicine Reports. 2016; 13(2): 1420–6. 45. Papadopoulos EI, Petraki C, Gregorakis A, et al. Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype. Biological Chemistry. 2016; 397(6): 529–39.
RkJQdWJsaXNoZXIy NDA4Mjc=